Navigation Links
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
Date:7/3/2009

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.

Study results showed excellent safety profile, and no serious adverse events were reported during the study. No patient dropped out due to adverse side effects of the treatment. Pharmacokinetic analyses showed no systemic exposure to the active ingredient of the product. Efficacy was assessed by performing instrumental measurements of skin lesion redness (erythema) and skin barrier function by trans-epidermal water loss (TEWL) during the 28-day period. Physician assessments, such as Eczema Area and Severity Index (EASI) were also evaluated. ProtoCure emulsion cream was superior to placebo in decreasing skin redness and improving skin barrier function. Statistically significant improvement was observed as early as day 10 after begining treatment. There was also a significant improvement in EASI score over the whole treatment period for ProtoCure emulsion cream as a sign of positive treatment effect. The EASI score difference did not reach statistical significance when compared to placebo, mainly due to the small number of patients studied.

"We are very pleased with the promising results of this study," says Lasse Leino, CEO of BioCis Pharma. "Skin barrier dysfunction is now recognized as a hallmark feature of atopic dermatitis. Any drug showing capacity for restoring this disturbance has significant potential in atopic dermatitis therapy. Based on our results, ProtoCure(TM) emulsion cream holds great promises in the treatment of inflammatory skin disorders."

Atopic dermatitis is a chronic inflammatory disease of the skin with an onset typically already in infancy. It affects up to 20 per cent of the general population in the Western countries, and the prevalence rate is rising. Atopic dermatitis may significantly impair the quality of life of those affected. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd. is a Karolinska Development portfolio company.

BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.

http://www.biocis.com

Contacts: Dr. Lasse Leino, CEO, BioCis Pharma Ltd., mobile phone +358-40-849-4694, lasse.leino@biocis.com


'/>"/>
SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
4. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
8. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
9. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):